<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1001">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04332094</url>
  </required_header>
  <id_info>
    <org_study_id>IIBSP-COV-2020-23</org_study_id>
    <nct_id>NCT04332094</nct_id>
  </id_info>
  <brief_title>Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of COVID-19</brief_title>
  <acronym>TOCOVID</acronym>
  <official_title>Pilot, Randomized, Multicenter, Open-label Clinical Trial of Combined Use of Hydroxychloroquine, Azithromycin, and Tocilizumab for the Treatment of SARS-CoV-2 Infection (COVID-19)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto de Salud Carlos III</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      COVID-19 is a respiratory disease caused by the new coronavirus (SARS-CoV-2) and causes
      considerable morbidity and mortality.

      Currently, there is no vaccine or therapeutic agent to prevent and treat a SARS-CoV-2
      infection. This clinical trial is designed to evaluate the use of Tocilizumab in combination
      with hydroxychloroquine and azithromycin for the treatment of hospitalized adult patients
      with COVID-19.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 2, 2020</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">September 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>In-hospital mortality</measure>
    <time_frame>Through hospitalization, an average of 2 weeks</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Need for mechanical ventilation in the Intensive Care Unit</measure>
    <time_frame>Through hospitalization, an average of 2 weeks</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">276</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Early administration of tocilizumab associated with hydroxychloroquine and azithromycin.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Treatment of SARS-COV-2 (COVID-19) infection with hydroxychloroquine and azithromycin.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tocilizumab</intervention_name>
    <description>162 mg sc x 2 doses + tocilizumab 162mg sc x 2 doses at 12 hours (day 1)</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>400 mg / 12h v.o. day 1 followed by 200 mg / 12h v.o. for 6 days (7 days in total)</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>500 mg / day v.o. for 3 days</description>
    <arm_group_label>Control</arm_group_label>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject (or authorized legal representative) who can provide written informed consent
             before beginning any study procedure.

          -  Understand and agree to abide by the study procedures.

          -  Adult #18 years of age at the time of inclusion in the study.

          -  Confirmation of SARS-CoV-2 infection by a microbiological test performed before
             randomization, no longer than 72 hours.

          -  Severity 3-4 according to the WHO 7-point ordinal scale.

        Exclusion Criteria:

          -  ALT / AST&gt; 5 times the normal limit

          -  Stage 4 chronic kidney disease (GFR &lt;30) or requiring dialysis.

          -  Presence of comorbidities that imply a poor prognosis (according to clinical
             judgment).

          -  Advanced dementia.

          -  Pregnancy or breastfeeding.

          -  Anticipation of transfer to another center in the 12 hours at the beginning of the
             study.

          -  Allergy to study medication.

          -  Serious or active bacterial infections or documented sepsis by pathogens other than
             SARS-CoV-2.

          -  Streptococcus pneumoniae antigenuria positive before study start.

          -  Neutropenia &lt;500 / mm3.

          -  Thrombocytopenia &lt;100,000 / mm3.

          -  History of diverticulosis.

          -  Ongoing skin infection (eg, pyodermitis).

          -  Transplanted patient under immunosuppressive treatment.

          -  Previous evidence of latent untreated tuberculosis.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Pere Domingo, MD, PhD</last_name>
    <email>pdomingo@santpau.cat</email>
  </overall_contact>
  <location>
    <facility>
      <name>Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pere Domingo, MD, PhD</last_name>
      <email>pdomingo@santpau.cat</email>
    </contact>
    <investigator>
      <last_name>Pere Domingo, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>March 31, 2020</study_first_submitted>
  <study_first_submitted_qc>April 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2020</study_first_posted>
  <last_update_submitted>April 5, 2020</last_update_submitted>
  <last_update_submitted_qc>April 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 7, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tocilizumab</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Azithromycin</mesh_term>
    <mesh_term>Hydroxychloroquine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

